AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38913710 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS SC 2.5 mg/kg
Number of subjects: 124
Study 38913710 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS SC 5 mg/kg
Number of subjects: 124
Study 38913710 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS IM 2.5 mg/kg
Number of subjects: 124
Study 38913710 — intervention group
Group type: COMPARATOR
Intervention: Placebo IM
Number of subjects: 124
Study 38913881 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab plus chemotherapy (n=762)
Number of subjects: 762
Study 38913881 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (n=539)
Number of subjects: 762
Study 38913881 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant placebo plus chemotherapy (n=383)
Number of subjects: 762
Study 38913881 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant placebo (n=308)
Number of subjects: 762
Study 38913882 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitBot (conversational chatbot)
Number of subjects: 179
Study 38913882 — intervention group
Group type: COMPARATOR
Intervention: SmokefreeTXT (text messaging program)
Number of subjects: 179
Study 38913933 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy added to standard neoadjuvant chemotherapy
Number of subjects: 0
Study 38913933 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy
Number of subjects: 0
Study 38913962 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 F-DPA-714 PET/CT imaging
Number of subjects: 13
Study 38913962 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 13
Study 38913998 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic period (January to December 2019)
Number of subjects: 9031
Study 38913998 — intervention group
Group type: COMPARATOR
Intervention: Early pandemic period (July 2020 to June 2021)
Number of subjects: 9031
Study 38913998 — intervention group
Group type: COMPARATOR
Intervention: Late pandemic period (July 2021 to June 2022)
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes during the pandemic
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnessed arrest
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrest at home or residence
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated external defibrillator use by bystanders
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: First monitored shockable rhythm
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital endotracheal intubation
Number of subjects: 9031
Study 38913998 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from cardiac arrest cognition to emergency department arrival
Number of subjects: 9031
Study 38914016 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
Number of subjects: 37
Study 38914016 — intervention group
Group type: EXPERIMENTAL
Intervention: 177 Lu-DOTATATE PRRT
Number of subjects: 37
Study 38914085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bailout angioplasty or stenting (BAOS)
Number of subjects: 348
Study 38914085 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (continue or terminate the thrombectomy procedure)
Number of subjects: 348
Study 38914124 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 3533
Study 38914124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3533
Study 38914224 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-fat (LC) diet for 4 days
Number of subjects: 11
Study 38914224 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate/low-fat (HC) diet for 4 days
Number of subjects: 11
Study 38914270 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rivaroxaban twice daily plus 100 mg aspirin daily
Number of subjects: 1000
Study 38914270 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin daily
Number of subjects: 1000
Study 38914270 — intervention group
Group type: COMPARATOR
Intervention: 5 mg rivaroxaban twice daily
Number of subjects: 1000
Study 38914294 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS with ranibizumab 100 mg/ml with fixed refill-exchanges every 24 weeks (Q24W)
Number of subjects: 418
Study 38914294 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental intravitreal ranibizumab injections
Number of subjects: 418
Study 38914294 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 418
Study 38914309 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Living (web-delivered psychosocial intervention)
Number of subjects: 256
Study 38914309 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyles (active control)
Number of subjects: 256
Study 38914313 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction and exercise intervention
Number of subjects: 24
Study 38914313 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 24
Study 38914469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic lung volume reduction (insertion of endobronchial valves)
Number of subjects: 19
Study 38914481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment with a 30% increase in intensity
Number of subjects: 60
Study 38914481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment
Number of subjects: 60
Study 38914694 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g ENSO 16
Number of subjects: 17
Study 38914694 — intervention group
Group type: COMPARATOR
Intervention: 30 g glucose
Number of subjects: 17
Study 38914876 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazo/Gaba 2.5/25 mg t.i.d. for 8 weeks
Number of subjects: 240
Study 38914876 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazo/Gaba 5/50 mg t.i.d. for 8 weeks
Number of subjects: 240
Study 38914876 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazo/Gaba 10/100 mg t.i.d. for 8 weeks
Number of subjects: 240
Study 38914876 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (Gaba)
Number of subjects: 240
Study 38914876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 240
Study 38914951 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary DCB angioplasty
Number of subjects: 2270
Study 38914951 — intervention group
Group type: COMPARATOR
Intervention: Primary stenting
Number of subjects: 2270
Study 38914959 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIs
Number of subjects: 1581
Study 38914959 — intervention group
Group type: COMPARATOR
Intervention: anti-VEGF
Number of subjects: 1581
Study 38914976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 10% spray (experimental group)
Number of subjects: 136
Study 38914976 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine hydrochloride infiltration (control group)
Number of subjects: 136
Study 38914974 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-face-to-face consultations
Number of subjects: 1000
Study 38914974 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 1000
Study 38915038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lever Positioning Manipulation (LPM) treatment, administered once every two days for a total of 12 times over 4 weeks.
Number of subjects: 60
Study 38915038 — intervention group
Group type: COMPARATOR
Intervention: Sham LPM treatment, administered during the same period as Group 1.
Number of subjects: 60
Study 38915038 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group 3) without LPM treatment.
Number of subjects: 60
Study 38915065 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (sulfasalazine and hydroxychloroquine)
Number of subjects: 122
Study 38915065 — intervention group
Group type: COMPARATOR
Intervention: TNFi (tumor necrosis factor inhibitor)
Number of subjects: 122
Study 38915097 — intervention group
Group type: EXPERIMENTAL
Intervention: EVA Nexus surgical platform
Number of subjects: 250
Study 38915103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Virtual Reality Environment (GVRE) treadmill rehabilitation program
Number of subjects: 8
Study 38915106 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid taper support program with PA intervention at weeks 1, 2, 4, 8, 12, 16, and 20 after discharge.
Number of subjects: 73
Study 38915106 — intervention group
Group type: COMPARATOR
Intervention: Usual care with standard hospital discharge instructions.
Number of subjects: 73
Study 38915111 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 80
Study 38915111 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 38915117 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaFiT therapy (bortezomib, lenalidomide, dexamethasone; daratumumab for frail patients)
Number of subjects: 90
Study 38915117 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaFiT therapy
Number of subjects: 90
Study 38915115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg PO every other day
Number of subjects: 90
Study 38915115 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg PO twice daily
Number of subjects: 90
Study 38915115 — intervention group
Group type: COMPARATOR
Intervention: Traditional blood glucose lowering therapy + ramipril 10 mg PO
Number of subjects: 90
Study 38915128 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and patient education intervention (eight tailored one-to-one sessions with trained providers)
Number of subjects: 200
Study 38915128 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 200
Study 38915130 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial vaccination
Number of subjects: 0
Study 38915130 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing resident and staff vaccination uptake to a target goal of 90%
Number of subjects: 0
Study 38915130 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent simulated removal of masking
Number of subjects: 0
Study 38915151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract (ME), injected subcutaneously three times a week for nine months
Number of subjects: 290
Study 38915151 — intervention group
Group type: COMPARATOR
Intervention: Placebo, injected subcutaneously three times a week for nine months
Number of subjects: 290
Study 38915151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe extract (ME)
Number of subjects: 290
Study 38915151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 38915264 — intervention group
Group type: EXPERIMENTAL
Intervention: Care partner burden
Number of subjects: 431
Study 38915356 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR embedded goal setting and preference survey with telephonic nurse care management for 6 months
Number of subjects: 100
Study 38915356 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control (EHR embedded survey after 6 months)
Number of subjects: 100
Study 38915423 — intervention group
Group type: EXPERIMENTAL
Intervention: Omigapil at daily doses ranging from 0.02 to 0.08 mg/kg for 12 weeks after a 4-week vehicle run-in.
Number of subjects: 20
Study 38915423 — intervention group
Group type: EXPERIMENTAL
Intervention: Omigapil
Number of subjects: 20
Study 38915796 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4-Ig and interleukin-2 (IL-2) therapy
Number of subjects: 4
Study 38915856 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of dietary nitrate supplementation (beetroot juice)
Number of subjects: 0
Study 38915856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38915873 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation migratory status
Number of subjects: 0
Study 38915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal antibiotics usage
Number of subjects: 0
Study 38915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section birth
Number of subjects: 0
Study 38915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study 38916221 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Educational Program (VREP) - viewed a VR-based educational video on the surgical process, 7-10 days prior to surgery.
Number of subjects: 241
Study 38916221 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Educational Program (VREP)
Number of subjects: 241
Study 38916221 — intervention group
Group type: COMPARATOR
Intervention: Control group - received oral/written information about the anaesthetic-surgical process and remained in a playroom waiting for surgery.
Number of subjects: 241
Study 38916221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241
Study 38916223 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (0.15 mg/kg/d for 5 days)
Number of subjects: 105
Study 38916223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 38916223 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 105
Study 38916263 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning discussions
Number of subjects: 22
Study 38916263 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of end-of-life preferences
Number of subjects: 22
Study 38916263 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to advance care planning
Number of subjects: 22
Study 38916263 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of advance care planning
Number of subjects: 22
Study 38916283 — intervention group
Group type: EXPERIMENTAL
Intervention: HUAWEI GT 3 Pro smartwatch
Number of subjects: 23
Study 38916283 — intervention group
Group type: COMPARATOR
Intervention: SphygmoCor
Number of subjects: 23
Study 38916283 — intervention group
Group type: EXPERIMENTAL
Intervention: pOpmètre
Number of subjects: 23
Study 38916421 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT001
Number of subjects: 25
Study 38916421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 38916425 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered ART
Number of subjects: 155
Study 38916425 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based ART
Number of subjects: 155
Study 38916429 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine with AS01B adjuvant
Number of subjects: 400
Study 38916429 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine with MF59 adjuvant
Number of subjects: 400
Study 38916429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose protein/adjuvant with AS01B
Number of subjects: 400
Study 38916429 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of DNA with AS01B-adjuvanted bivalent Env gp120
Number of subjects: 400
Study 38916429 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01B-adjuvanted regimens
Number of subjects: 400
Study 38916429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 38916429 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 400
Study 38916700 — intervention group
Group type: EXPERIMENTAL
Intervention: DCISionRT test
Number of subjects: 2496
Study 38916717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat (10 mg target dose)
Number of subjects: 0
Study 38916717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study 38916753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified in the abstract
Number of subjects: 47
Study 38916892 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous buprenorphine
Number of subjects: 428
Study 38916892 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine-naloxone
Number of subjects: 428
Study 38916892 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 428
Study 38917081 — intervention group
Group type: EXPERIMENTAL
Intervention: Early assessment and intervention by a dedicated Health and Social Care Professionals (HSCP) team in the ED
Number of subjects: 353
Study 38917081 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 353
Study 38917099 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for family planning at EPI units
Number of subjects: 1421
Study 38917111 — intervention group
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (VDOT) for hydroxyurea
Number of subjects: 100000
Study 38917111 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 100000
Study 38917212 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment using Clinical Frailty Scale
Number of subjects: 0
Study 38917366 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmethadone (REL-1017)
Number of subjects: 0
Study 38917366 — intervention group
Group type: COMPARATOR
Intervention: Standard antidepressants
Number of subjects: 0
Study 38917371 — intervention group
Group type: EXPERIMENTAL
Intervention: Eflornithine (IWILFIN)
Number of subjects: 0
Study 38917371 — intervention group
Group type: COMPARATOR
Intervention: External Control (derived from Study ANBL0032)
Number of subjects: 0
Study 38917400 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Education (SE)
Number of subjects: 247
Study 38917400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 247
Study 38917400 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 247
Study 38917404 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient high-dose methotrexate (HD-MTX) with glucarpidase 2000u
Number of subjects: 7
Study 38917525 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily plus mesalamine 1 g three times daily for 6 months
Number of subjects: 60
Study 38917525 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 1 g three times daily for 6 months
Number of subjects: 60
Study 38917696 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic and Visual Imagery Questionnaire-10 (KVIQ-10)
Number of subjects: 38
Study 38917696 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 38
Study 38917793 — intervention group
Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 154
Study 38917793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 38918103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster (5 × 10^10 viral particles)
Number of subjects: 0
Study 38918103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster (other dose levels)
Number of subjects: 0
Study 38918103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38918235 — intervention group
Group type: EXPERIMENTAL
Intervention: Atoguanil™
Number of subjects: 0
Study 38918235 — intervention group
Group type: COMPARATOR
Intervention: Malarone® (atovaquone-proguanil hydrochloride)
Number of subjects: 0
Study 38918556 — intervention group
Group type: EXPERIMENTAL
Intervention: Stacking model for predicting axillary lymph node (ALN) response to neoadjuvant chemotherapy (NAC) using longitudinal MRI.
Number of subjects: 1153
Study 38918556 — intervention group
Group type: COMPARATOR
Intervention: Radiologists' assessment of ALN response to NAC.
Number of subjects: 1153
Study 38918556 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of disease-free survival between high-risk and low-risk groups.
Number of subjects: 1153
Study 38918590 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical simvastatin
Number of subjects: 24
Study 38918590 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atorvastatin
Number of subjects: 24
Study 38918590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 38918630 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable thermal ablation (TA) device
Number of subjects: 3124
Study 38918630 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 3124
Study 38918630 — intervention group
Group type: COMPARATOR
Intervention: Large loop excision of transformation zone (LLETZ)
Number of subjects: 3124
Study 38918695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Number of subjects: 124
Study 38918695 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 124
Study 38918695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 124
Study 38918780 — intervention group
Group type: EXPERIMENTAL
Intervention: TB/TBI treatment
Number of subjects: 11
Study 38918806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body 18FDG-PET/CT scans in patients with microbiologically confirmed spinal tuberculosis
Number of subjects: 0
Study 38918869 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques with 12 weeks of direct acting antiviral (DAA) treatment
Number of subjects: 20
Study 38918871 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (subcutaneous)
Number of subjects: 219
Study 38918903 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transsphenoidal surgery
Number of subjects: 35
Study 38918903 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score ≥ 3
Number of subjects: 35
Study 38918903 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical acromegaly remission
Number of subjects: 35
Study 38918903 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in REI
Number of subjects: 35
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with comorbid conditions
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with one comorbid condition
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with two comorbid conditions
Number of subjects: 25454